Candel Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies designed to elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company's clinical pipeline is built on two distinct platforms: a genetically modified adenovirus platform and a herpes simplex virus (HSV) platform. Its most advanced candidate is aglatimagene besadenovec (also known as CAN-2409), a replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly into a patient's tumor. When combined with subsequent oral valacyclovir administration, aglatimagene besadenovec induces immunogenic cell death, releasing tumor-specific antigens and broadly activating the patient's immune system against the cancer. Candel is also developing CAN-3110 (linoserpaturev), an investigational HSV-based immunotherapy currently in Phase 1b clinical trials for recurrent high-grade glioma.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out commercial capabilities, medical affairs, and launch readiness activities for aglatimagene besadenovec (CAN-2409) in localized prostate cancer ahead of the planned Q4 2026 BLA submission.
Expected impact: Enables a rapid and efficient commercial launch in the U.S. upon potential FDA approval in 2027.
Initiating a pivotal Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor treatment.
Expected impact: Expands the addressable market for Candel's lead asset into late-stage lung cancer.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
EVERSANA will provide a broad suite of integrated commercialization services, including data and analytics, medical affairs, market access, and field operations, to support the potential U.S. commercial launch of aglatimagene besadenovec.
Terms: Not disclosed; designed as a partner-led model to maintain capital efficiency.
Secures non-dilutive funding to support the potential U.S. commercial launch of aglatimagene besadenovec in localized prostate cancer.
Terms: RTW committed $100 million in funding contingent upon FDA approval of aglatimagene besadenovec. In return, RTW will receive a tiered single-digit percentage of annual net sales in the U.S. (4.67% on annual sales up to $1 billion and 1.33% on sales above that level), subject to a $250 million royalty cap.
IDEA Pharma provides strategic commercial input, path-to-market strategies, and strategic positioning throughout the development and commercialization process for aglatimagene besadenovec.
Terms: Not disclosed; partnership expected to run through 2026.